Plus Therapeutics

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacturing, and commercialization of treatments for patients with cancer and other diseases. The company’s lead product candidate, Rhenium NanoLiposomes, is a patented radiotherapy for patients with recurrent glioblastoma, currently in a Phase 1 dose-escalation clinical trial. Plus Therapeutics is also developing DocePLUS, a patented chemotherapy for patients with solid tumors, which is currently in a Phase 1 clinical trial.